Genomic Health (GHDX) Lowered to “Sell” at ValuEngine
Genomic Health (NASDAQ:GHDX) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday.
Several other research analysts also recently commented on the stock. Zacks Investment Research raised shares of Genomic Health from a “sell” rating to a “hold” rating in a report on Tuesday, February 13th. Canaccord Genuity reaffirmed a “buy” rating and issued a $42.00 price objective on shares of Genomic Health in a report on Tuesday, January 16th. Barclays reaffirmed a “sell” rating and issued a $28.00 price objective on shares of Genomic Health in a report on Monday, January 8th. William Blair downgraded shares of Genomic Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, December 20th. Finally, BidaskClub raised shares of Genomic Health from a “sell” rating to a “hold” rating in a report on Tuesday, December 19th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $32.33.
Shares of Genomic Health (NASDAQ GHDX) traded up $1.03 during mid-day trading on Thursday, hitting $31.94. 280,511 shares of the stock traded hands, compared to its average volume of 226,609. Genomic Health has a 12 month low of $26.54 and a 12 month high of $37.50.
Large investors have recently made changes to their positions in the business. Meeder Asset Management Inc. boosted its holdings in Genomic Health by 120.7% in the 4th quarter. Meeder Asset Management Inc. now owns 2,960 shares of the medical research company’s stock valued at $101,000 after purchasing an additional 1,619 shares during the period. Cubist Systematic Strategies LLC bought a new position in Genomic Health in the 3rd quarter valued at $138,000. Jane Street Group LLC bought a new position in Genomic Health in the 3rd quarter valued at $227,000. Teacher Retirement System of Texas bought a new position in Genomic Health in the 4th quarter valued at $242,000. Finally, Virtu Financial LLC bought a new position in Genomic Health in the 4th quarter valued at $261,000. 90.20% of the stock is owned by hedge funds and other institutional investors.
WARNING: “Genomic Health (GHDX) Lowered to “Sell” at ValuEngine” was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/genomic-health-ghdx-lowered-to-sell-at-valuengine/1905530.html.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.